Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sunburned blasts: ultraviolet imprints on aneuploid pediatric leukemia.

Haematologica·2026
Same author

Stable, thus in critical condition: m6A-methylated fusion transcripts in B-cell acute lymphoblastic leukemia.

Haematologica·2026
Same author

<i>QKI</i> dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.

Haematologica·2026
Same author

Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity.

Cell death & disease·2026
Same author

T cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges.

The Journal of clinical investigation·2025
Same author

NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT/β-catenin pathway.

Haematologica·2025

Related Experiment Video

Updated: Jul 7, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K

Knocking off cancer's HAT: CSS1477 disrupts oncogenic programs.

Luyao Kevin Xu1, Panagiotis Ntziachristos2

  • 1Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Bioscience, Oncology R&D, AstraZeneca, Waltham, MA, USA.

Cell Chemical Biology
|December 22, 2023
PubMed
Summary
This summary is machine-generated.

New research shows the small-molecule inhibitor CSS1477 shows promise for targeting EP300/CBP in blood cancers. This offers a potential new treatment option for patients with no other therapeutic choices.

More Related Videos

Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines
10:46

Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines

Published on: June 2, 2018

9.4K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.8K

Related Experiment Videos

Last Updated: Jul 7, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines
10:46

Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines

Published on: June 2, 2018

9.4K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • EP300 and CBP are crucial histone acetyltransferases involved in gene regulation.
  • These proteins are recruited to chromatin by oncogenic transcription factors.
  • Their activity in enhancer regions controls cellular transcriptional programs.

Purpose of the Study:

  • To evaluate the therapeutic potential of the small-molecule inhibitor CSS1477.
  • To investigate CSS1477 as a targeted therapy for blood tumors.
  • To offer new treatment avenues for patients with limited options.

Main Methods:

  • Utilized the small-molecule inhibitor CSS1477.
  • Focused on targeting EP300/CBP histone acetyltransferases.
  • Clinical application in patients with blood tumors was considered.

Main Results:

  • CSS1477 demonstrates promise in targeting EP300/CBP.
  • The inhibitor offers potential for treating blood malignancies.
  • Provides a novel therapeutic strategy for refractory cases.

Conclusions:

  • Targeting EP300/CBP with CSS1477 presents a promising therapeutic strategy.
  • This approach may benefit patients with blood tumors lacking other options.
  • Further research into CSS1477 efficacy is warranted.